XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 546 participants.

Also called NCT01178268

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 546 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01178268
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01178268. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-10 (actual). Results posted on 2016-08-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
Condition
Coronary Occlusion
Condition
Thrombosis (Stent Thrombosis)
Condition
Vascular Disease
Condition
Myocardial Ischemia
Condition
Coronary Artery Stenosis
Condition
Coronary Disease
Condition
Coronary Restenosis
Intervention (Device)
XIENCE V EECSS
Intervention (Device)
CYPHER SELECT PLUS SECSS
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct01178268
Content hash
85135a23669b2b5275f281675ec11bd6ed5b3d6418e7a234ec62d875446bdff5